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InterventionAbstract Ventilator-associated pneumonia (VAP) is the most prevalent infection in intensive care
units (ICU). To reduce this rate, the application of bundles – groups of individual practices and
adherence to the best nursing practices from Association for Professionals in Infection Control
and Epidemiology (APIC) guidelines (2009) is recommended.
This study aimed: This study aimed to estimate the microbiology including; rate of VAP,
mortality rate attributed to VAP, among (ICU) critically ill patients and evaluate the effectiveness
of adherence to VAP bundle on elimination of infection, also cost effectiveness as reflection to
length of stay in ICU.
Subject and methods: A comparative interventional design was used to achieve the aim of the
study. It is conducted in 14 bedded Adult Medical-surgical ICU.VAP Bundle Program was
implemented by our multidisciplinary team (pulmonologist, microbiologist, intensivist and ICU
nurses). The VAP bundle team starting the program implementation in January 2014 till the
end of December 2015 (follow up prospective study), all those patients underwent daily 5 items
1- bed elevation, 2- DVT prophylaxis, 3- peptic ulcer prophylaxis, 4- oral hygiene and 5- sedation
break and weaning assessment. Surveillance reports from ICU for the year 2013 were reviewed
(retrospective study). Data were collected and analyzed for (VAP) and compared before and after
VAP bundle intervention.
Results: All ventilated patients who met the inclusion criteria were grouped in two groups,
group A (130) patients non bundle used and group B (250) patient vap bundle used, then sub
grouped to VAP and non VAP for statistical analysis, mean age in vap patients was higher in
both groups, VAP incidence in group A 18.5% that decreased significantly to half of 9% in group
B, p value <0.05, also VAP rate/1000 ventilated day showed a statistically significant difference
between group A 25/1000 day in 2013 to VAP rate in 2014 year, 8.5/1000 ventilator days, also to
VAP rate 6/1000 ventilator days in 2015, p value <0.007. Strong significant negative correlation
between compliance of VAP bundle and VAP rate was found, p< 0.0001, VAP bundleEgypt.
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J. Chest Dis. Tuberc. (2016), http://dx.doi.orcompliance ranged from 94% to 100%. Male and medical patients were higher in both groups
more than 62%, outcome improved after bundle as the death rate decreased in group B in both
subgroups than that in group A, and length of stay in ICU was lowered significantly in group B
about 2 days subsequently lowering the cost.
Conclusion: The application of VAP bundle is a feasible reality that produces improvement in
microbiological measures and nosocomal infection rates resulting in lowering mortality, shortened
lengths of hospitalization and decreased medical care costs. However, education and periodic
training remain a fundamental process of improving health services. VAPs were reduced by
improving bundle compliance and ensuring the same standard of care to all ICU patients. Direct,
on-site observation was a more accurate method of monitoring.
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Ventilator-associated pneumonia (VAP) is an airways infec-
tion that must have developed more than 48 h after the patient
was intubated. It accounts for up to 47% of all infections
among ICU patients [1]. It has been reported that VAP can
occur in 9–27% of all intubated patients [2] and accounts for
86% of nosocomial pneumonia [3].
Systemic review on VAP in developing countries was
published in 2008 and found that VAP rates varied from
10 to 41.7 per 1000 ventilator-days, which were generally
higher than the National Healthcare Safety Network (NHSN)
rates [4].
VAP can result from either colonization of the aerodiges-
tive tract with pathogenic bacteria or aspiration of gastric con-
tents that serve as reservoir of many organisms, aerobic gram
negative bacilli are most frequently isolated including
Escherichia coli, Klebsiella pneumonia, Pseudomonas aerugi-
nosa, Enterobacter spp, Serratia spp. and Acinetobacter
spp., especially in patients with underlying serious disease [5].
When VAP occurs, it prolongs ICU length of stay,
increases medical care costs and increases morbidity and mor-
tality [6], the cost of VAP can be explained by increased length
of stay in ICU by 5–7 days, also increased hospital stay length
2–3 folds among VAP patients [7], the higher mortality rates
among VAP patients explained by some authors as higher
antibiotic resistance 43% in causative agent isolated [8].
For reducing VAP mortality an organized process that
guarantees early recognition of pneumonia and continuous
application of evidence-based practice, so the Institute for
Healthcare Improvement (IHI) developed a series of interven-
tions related to ventilator care-VAP bundle- that should be
implemented together to achieve the best outcome [9].
Although the optimal approach for reducing ventilator-
associated pneumonia is unclear, studies reported that educat-
ing health care providers caring for patients on mechanical
ventilation can decrease the rate of ventilator-associated
pneumonia [10].
A multidimensional strategy that included a bundle of
infection control interventions, education process and outcome
surveillance then feedback on VAP rates was associated with a
significant reduction in VAP rate in ICUs in developing
countries [11].
VAP bundle was tried and applied to reduce VAP in ICUs
but has not been studied well in developing countries, also
various bundle elements differ according to the medical team,et al., Impact of VAP bundle adherence
g/10.1016/j.ejcdt.2016.08.010Thomas 2016 concluding that for preventing VAP, combining
a core set of prevention measures into a bundle is a practical
way to enhance care [21].
Aim of the work
The primary outcome of this current study was the evaluation
of adherence to VAP bundle and its effect on VAP rates and
mortality, while the secondary outcome was the cost saving
resulting from implementation of VAP bundle.
Patients and method
Setting
This study was conducted in open adult ICU, 14 bed, nurse to
bed 1:1 in which hand hygiene was applied since 2010 with a
compliance rate more than 95% in the last 3 years. All venti-
lated patients from January 2014 included in the prospective
study until the end of December 2015; those patients were
studied and followed carefully by the team (pulmonologist,
intensivist, microbiologist and ICU nurses).
Design
All patients who were mechanically ventilated for P48 h and
18 years of age, then we exclude those who were ventilated
due to severe pneumonia, or intubated outside our
hospital, and if there is any contraindication to one of the
VAP bundle items (hemorrhage, neck surgery and if allergic
to H2 blocker or chlorhexidine), in the period from January
2014 to the end of December 2015 and we compared them with
the ventilated patient in our ICU in 2013 retrospectively. We
divided them into 2 main groups, group A that included
patients who were ventilated in 2013, and group B those
who were ventilated with VAP bundle application in 2014
and 2015.
All critical care nurses and staff were educated and made
aware about VAP and the importance of the use of VAP bun-
dle to decrease this nosocomial infection, VAP was diagnosed
as per the Center of Disease Control (CDC) as a pneumonia
that occurs in a patient who was intubated and ventilated
within or more than 48 h according to the following criteria:
new or progressive infiltrates, consolidation or cavitations on
chest X-ray with one of the following;among ventilated critically ill patients and its eﬀectiveness in adult ICU, Egypt.
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b- Leucopenia (white blood cell < 1500/mm3) or leukocy-
tosis (>12,000/mm3).
c- Core temperature >38 C or <36 C without other
cause.
d- Positive culture from blood, bronchoalveolar lavage or
endotracheal aspirate.
Prospective study from January 2014 to the end of Decem-
ber 2015, all patients on mechanical ventilations underwent by
the team in the following steps:
1- VAP bundle items application.
2- Daily clinical examination by pulmonologist.
3- Fever chart 4 times daily.
4- Chest X-ray before intubation then daily.
5- Tracheal aspirate (sputum) chart daily.
6- VAP rate monitoring as the number of infections per
1,000 ventilator-day and ranking on monthly basis
through the study period.
7- Measurement of VAP bundle compliance daily and
ranking it monthly;
compliance¼ No:receiving all bundle components
0
No:of patients on ventilator of the day of sample8- Daily complete blood count (CBC).
9- Microbiological culture of tracheal aspirate and bron-
choalveolar lavage as ordered.
VAP bundle items were chosen as recommended by CDC
2010, during our study of CDC in 2014 the same items were
continued so we did not change anything, these implemented
bundles included:
1- Bed elevation greater than 30 up to 45.
2- Dvt prophylaxis.
3- Peptic ulcer prophylaxis (H2 blocker).
4- Oral hygiene with chlorhexidine (15 ml twice daily until
24 h after extubation).
5- Daily sedation break and assessment of weaning.
VAP rate expressed as:
Total No:of VAP cases 1000
Ventilator daysTable 1 Cumulative VAP incidence between both groups.
Group A (n= 130) Group B (n= 250) p
Vap incidence 24 (18.5%) 23 (9%) <0.05Result
This study was conducted on three hundred and eighty
patients, two hundred and fifty were prospectively observed
through two years (group B), while a hundred and thirty
patients were retrospectively reviewed over one year (group
A). All patients were ventilated with invasive mechanical ven-
tilation that lasting 48 h and more. Each group was sub-
classed into VAP and non VAP. In group A, the number of
patients who have VAP was 24(18.5%) and the non VAP
was 106(81.5%), while in group B, the number of patients with
VAP was 23(9%) and those non VAP was 227(91%) with sta-
tistically significant difference in between both groups p value
<0.05 Table 1. Regarding age distribution, patients with VAPPlease cite this article in press as: S.R. Samra et al., Impact of VAP bundle adherence
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statistically significant difference between them. Age distribu-
tion among patients with VAP was 65 ± 26 years in group A
versus 69 ± 24 years in group B while it was 50 ± 25 years
in group A versus 48 ± 33 in group B among non VAP
patients Table 2. The result of the current study showed that
male patients represent a higher percentage in both study
groups either with Vap or without VAP and also, mechanical
ventilation due to medical causes was higher than surgical
causes without statistically significant difference in both
groups in the same category Table 3. As regards mortality, this
study documented that death rate was decreased among VAP
patients from 38% in group A to 30% in group B, also it was
decreased in non VAP patients from 9% in group A to 4% in
group B, without statistically significant difference, Table 3.
Length of stay (LOS) was low among VAP patients in group
B, (12.2 ± 4.6 day) when compared with group A(14
± 6.2 day) while it was(10.4 ± 5.5 day) among non VAP
patients in group A versus (8.6 ± 4.4 day)in group B with sta-
tistically significant difference with p value < 0.05 Table 3. In
our study the mean VAP rate was 25/1000 ventilator days in
2013 before VAP bundle application then decreased to
8.5/1000 ventilator days after bundle application in 2014,
down to 6/1000 day in 2015 with statistically significant differ-
ence between group A (2013) and group B (2014–2015) with
p= 0.007 and 0.001 respectively Table 4. VAP rate Zero
was recorded during some months especially in 2015 Table 4
Compliance of VAP bundle was measured for total items daily
and recorded in a prospective manner, in group B compliance
rate was achieved between 94% and 100% Table 5. In group B
there is a statistically significant negative correlation between
compliance and VAP rate/1000 ventilator days through 2014
and 2015 on monthly bases, r= 0.86, p= 0.0001, Fig. 1.
Discussion
Ventilator associated pneumonia is the most common infection
in ICUs. VAP incidence ranges from 10% to 40% of patients
receiving mechanical ventilator [1]. VAP is a serious complica-
tion of invasive mechanical ventilation and is associated with
significant morbidity and mortality, so prevention of nosoco-
mial infections, including VAP was identified as a priority area
for national action by the institute of medicine [12].
Center for Disease Control and Prevention (CDC) started a
long time ago to publish guidelines for the prevention of noso-
comial pneumonia as in 1983 it was focused on preoperative
prevention measures, then those guidelines were revised at
1997 and included measures to decrease aspiration, prevent
cross-contamination or colonization of health care workers’
hand and reduction of oropharyngeal and gastric colonization
of pathogenic microorganisms [13].
In 2003, guidelines were updated, expanded and focused in
preventing health care associated pneumonia, especially VAP
[14] and the definition of VAP was done depending onamong ventilated critically ill patients and its eﬀectiveness in adult ICU, Egypt.
Table 3 Patients’ characteristics in both study groups.
Group A (n= 130) Group B (n= 250) p
Vap (n= 24) Non vap (n= 106) Vap (n= 23) Non vap (n= 227)
Male 18(75%) 70(66%) 16(70%) 154(68%) 0.6
Female 6(25%) 36(34%) 7(30%) 73(32%) 0.36
Medical 17(71%) 66(62%) 15(65%) 152(67%) 0.57
Surgical 7(29%) 40(38%) 8(35%) 75(33%) 0.43
Death 9(38%) 10(9%) 7(30%) 10(4%) 0.3
LOS 14 ± 6.2 10.4 ± 5.5 12.2 ± 4.6 8.6 ± 4.4 <0.05
Table 4 Vap rate/1000 days monthly distribution throughoutthe study.
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Mean
2013 16 28 32 26 18 20 28 30 22 26 24 30 25
2014 16 14 12 0 0 18 10 8 0 12 12 0 8.5
2015 0 12 10 18 4 13 0 0 10 0 6 0 6
*p 2013 vs 2014 = 0.007; *p 2013 vs 2015 = 0.001; *p 2014 vs 2015 = 0.33.
Table 5 Compliance of vap bundle.
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2014 94 96 97 100 98 94 98 97 98 96 95 100
2015 98 96 97 95 99 96 98 98 97 98 99 100
P= 0.67.
Table 2 Age distribution between study groups.
Group A (n= 130) Group B (n= 250) p
VAP (n= 24) Non VAP (n= 106) VAP (n= 23) Non vap (n= 227)
Age 65 ± 26 50 ± 25 69 ± 24 48 ± 33 0.76
Figure 1 Correlation between compliance and VAP rate/1000 ventilator days R= 0.8605; p< 0.0001.
4 S.R. Samra et al.microbiology, radiology and clinical diagnosis, also applica-
tion of VAP bundle as a collective preventive measure started
to be applied as protocols and known identified elements [14].Please cite this article in press as: S.R. Samra et al., Impact of VAP bundle adherence
J. Chest Dis. Tuberc. (2016), http://dx.doi.org/10.1016/j.ejcdt.2016.08.010In 2010 5 items were approved as VAP bundles that we used in
our study aiming to evaluate its impact and efficacy on VAP
prevention or modification.among ventilated critically ill patients and its eﬀectiveness in adult ICU, Egypt.
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ICU was 18.5% in 2013 before the VAP bundle and decreased
to 9% after bundle application with statistically significant dif-
ference, Kamel A.M (2014), found in his study a significant
lowering in VAP incidence from 34% to 18% after his bundle
application [15]. Instead of that our results were more valuable
and at a lower rate compared to his results before and after
bundle application as we applied strict hand hygiene policy
in our ICU from 2010 with compliance of more than 95%
monthly until the end of study.
In the current study we found that VAP was favorable with
aging, mean age ± standard deviation (SD) was 65 ± 25 year
and 69 ± 24 year in VAP patients in group A and B respec-
tively, and in non-VAP it was 50 ± 25 years in group A versus
48 ± 33 years in group B, in contrast with most of the studies
that showed that mean age of VAP groups was less than non
VAP groups, this may be due to that the age range in this study
ranged from 18 to 105 years, also age is one of the most impor-
tant risk factors for VAP especially if more than 70 years [16].
VAP rate was higher in group A in our ICU 25/1000 ventilator
days but in the range that was documented by Arabi et al.
(2008) in his systematic review as the VAP rate in developing
countries varied from 10 to 41.7/1000 ventilator days [3],
VAP rate was significantly decreased in group B to 8.5/1000
ventilator days with a p value = 0.007 in the first year (2014)
after bundle application, then more improvement was achieved
in the second year (2015), as the VAP rate declined to 6/1000
ventilator days with a p value = 0.001. Achievement of Zero
rate was done in some months but was not sustained due to
many factors like underlying diseases, Glasgow Coma Scale
(GCS) and resistant organisms. Zero VAP rate was doubtful
to be achieved by many experts [17], nevertheless more than
50% of nonteaching medical ICUs in the United States have
reported the VAP rate to be Zero [18], our results were in
agreement with this and we already achieved it some months
after strict bundle application. Zero rate needs high awareness
and compliance of all staff and also the reliability of bundle
compliance is one of the important factors. Compliance rate
was high up to 94% and reached 100% in some months com-
pared to other studies in which it was difficult to achieve 95%
compliance through their studies [15,19]. We reached this score
as we have trained ICU nurses, also we used the VAP bundle
as a local policy in our ICU, in ventilated patients, and all
mechanically ventilated patients were not included in this
study, only patients who met our inclusion criteria.
The results of the current study showed a significant
negative correlation between compliance and VAP rate/1000
ventilator days on a monthly basis with a p value < 0.0001.
These results as regards significance lowered VAP infection
in our ICU, showed high compliance, and a significant nega-
tive correlation between them, and achieved our primary goal
as it disclosed good adherence and beneficial bundle
application.
The results of the current study showed that patients report
a higher male percentage in both study groups either with VAP
or without VAP and also mechanical ventilation due to medi-
cal causes was higher than surgical causes, with nearly similar
results that were found in Saudi Arabia in 2012 by Hasan
et al., as they found the male percentage in the VAP group
was 73% and medical causes of intubation were 73% in the
same group [19].Please cite this article in press as: S.R. Samra et al., Impact of VAP bundle adherence
J. Chest Dis. Tuberc. (2016), http://dx.doi.org/10.1016/j.ejcdt.2016.08.010Outcome of ventilated patients in this study regarding
mortality and LOS in ICU was improved as mortality was
38% in-between VAP patients group A, that come down to
30% in VAP patients group B, and from 9% to 4% in non
VAP patients in groups A and B respectively with no statisti-
cally significant difference, this result in our study after VAP
bundle implementation, was lesser than that recorded by
American Thoracic Society (ATS) 2005 of VAP mortality,
and was between 33% and 50% [20]. LOS was decreased
significantly among mechanically ventilated patients in our
ICU in group B either VAP or non VAP subgroup after bundle
application nearly 2 days less, this statistically significant low-
ering in LOS was recorded in many studies [15,19]. which was
reflected by decreased financial support and medical staff
effort, that result achieved our secondary goal that is decreased
cost from nearly 2000 to 3000$ per case.
On conclusion, the application of the VAP bundle is a fea-
sible reality that produces improvement in microbiological
measures and nosocomial infection rates resulting in lowering
mortality, shortened lengths of hospitalization and decreased
medical care costs. However, education and periodic training
remain a fundamental process of improving health services.
VAPs were reduced by improving bundle compliance and
ensuring the same standard of care to all ICU patients. Direct,
on-site observation was a more accurate method of
monitoring.
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